Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced the selection of an abstract for presentation at the European Hematology Association (EHA) Virtual Congress which will take place June 9 to 17, 2021.
NEW YORK and BASEL, Switzerland, May 12, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the selection of an abstract for presentation at the European Hematology Association (EHA) Virtual Congress which will take place June 9 to 17, 2021. The data is on ARU-1801, a one-time gene therapy designed to cure sickle cell disease (SCD). The abstract is now available on the EHA website at ehaweb.org and the poster presentation will be available on June 11, 2021. "The data being presented at EHA demonstrate that it is possible to tailor the reduced intensity melphalan dose required prior to infusing ARU-1801, a potentially curative gene therapy for sickle cell disease patients," said Will Chou, M.D., chief executive officer of Aruvant. "Some patients with SCD process melphalan differently than others. The data emerging from our Phase 1/2 trial is important because it highlights an opportunity to individualize our reduced intensity conditioning dose of melphalan and maximize the potential for ARU-1801 to engraft. The unique promise of ARU-1801 is combining the favorable toxicity profile of RIC with the potential for a cure." The poster presentation will review the potential of a model-based, individualized melphalan dosing strategy for ARU-1801 in SCD. Melphalan exposure (AUC) after a single dose of 140 mg/m2 conditioning was observed in three patients with SCD in the ongoing Phase 1/2 MOMENTUM study and compared to predictions from a population pharmacokinetics (PK) model, based on patient covariates collected prior to melphalan infusion. These data suggest that a simple algorithm for individualized melphalan dosing based on a few covariate values has potential to achieve optimal melphalan exposure and reduce variability, which may result in improved patient outcomes after treatment with ARU-1801. Presentation Information About Aruvant Sciences About Roivant
SOURCE Aruvant Sciences |